Novo Nordisk A/S Class Action Lawsuit - NVO

According to the complaint, on December 20, 2024, Novo issued a press release announcing the below-expected results of their “REDEFINE 1” trial, “a 68-week efficacy and safety trial investigating subcutaneous CagriSema.” The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks, well short of Novo’s targeted expectation of at least 25% weight loss. The press release further indicated that participant patients were permitted to modify their own dosage during the trial and, as a result, only 57.3% of patients treated with CagriSema were on the highest dosage contemplated by the study. Following this news, Novo’s stock price fell by $18.44 per share to close at $85.00 per share.

In order to be eligible to join the NVO class action lawsuit, you must have incurred a loss on shares of Novo purchased during the class period listed above.

If you suffered a loss in Novo during the relevant time frame or pursuant to the relevant offering(s), you have until March 25, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.